Nutri-Med Logic Corp. Says The Benefits of Omega-3 in Alzheimer’s Are Associated With the Duration of Its Supplementation, According to a Recent Study

Miami, Florida (PRWEB) October 31, 2011

Nutri-Med Logic Corp: A new study, published in The Journal of Alzheimers Disease, states the previous studies have demonstrated that patients with very mild Alzheimer’s or mild cognitive impairment benefited from omega-3 treatment, but none showed significant improvements in cognitive function in patients with moderate or advanced Alzheimer’s.

The study, further, states that all those Randomized Control Trials, showing no effect, had a relatively short duration of supplementation and a systematic review and meta-analysis on effects of the relatively long-term omega-3 FA supplementation (minimum period; 10% of average total lifespan) showed a reduction in the amount of amyloid- in experimental animal. Amyloid- is the key aspect of Alzheimers Disease.

Nutri-Med Logic Corp adds that while the duration of supplementation would, obviously, tilt the conclusion, the intake amount of Omega-3 would do likewise.

The interest in Omega-3 and Alzheimer’s arises from its anti-inflammatory and neuro- protective properties, in one side, and the role of inflammation in the progression of Alzheimer’s in the other side.

According to Mayo Clinic, chronic inflammatory reactions are present in Alzheimer’s disease. A protein called amyloid-beta (A) forms sticky “plaques” in the brains of people with Alzheimer’s disease, eventually destroying the brain cells (neurons) and resulting in memory loss.

In animal studies, inflammatory stress was directly related to the amount of soluble and insoluble A present in the brain suggesting that pathological accumulation of A is a key factor for the neuro-inflammatory response.

Inflammation, an immune mechanism, starts from the cellular membranes through a group of short-lived local hormones (Prostaglandins-2), which are the derivatives of the fatty acids of Omega-6.

The primary mechanism for the resolution of the inflammation also starts from the cellular membrane and through a group of short-lived local hormones (Prostaglandins-3) but these are the derivatives of the fatty acids of Omega-3.

The membrane ratio of Omeg-3/Omega-6 dictates the intensity and the duration of immune responses. Both Omega-3 and Omega-6 are only obtained from food.

Diets lacking cold-water fishes (richest source of Omega-3) tilt the balance to the pro-inflammatory Omega-6. Even diets containing cold-water fishes carry a big question mark: The actual delivery of Omega-3 from cooked or fried fishes, since Omega-3 is sensitive to heat.

The natural moderation of inflammation, as it relates to Omega-6, can only be attained through supplementation of Omega-3, a competitor of Omega-6.

Due to the scarcity of Omega-3 in food, the human body has evolved and adjusted itself to favor Omega-3 over Omega-6, as evidenced by the rate of conversion of their precursors: 2.3% (Omega-6) v. 18.5% (Omega-3). (Emaken et al., 1992.).

To determine if the sustained inflammatory responses are due to lack of membrane Omega-3, duration and the intake amount are of paramount importance.

To make a parallel comparison, even if not fully appropriate, to draw a conclusion on effectiveness of penicillin from the results of a study incorporating 500mg of penicillin for 2 days, when 2000mg were needed for 10 days, would be the same as drawing conclusion on an inadequate amount of Omega-3 for a less-than-sufficient period of time.

It is important to note that the role of Omega-3 in not exclusive to only an anti-inflammatory property in Alzheimers. Omega-3 is a precursor to Neuroprotectin D1, which helps to safeguard neurons from premature death.

Currently, there are not even a DRI (Daily Reference Intake) on Omega-3, even though the human body is incapable of producing it and Omega-3 is considered essential!

As to Omega-3 and diseases, the only credible guideline published until now has been put forth by Dr. Paula R. Trumbo, of The Division of Nutrition Programs and Labeling of FDA, relating to cardiovascular benefits of Omega-3.

Dr. Trumbo Surrogate endpoints for Cardiovascular Disease and EPA/DHA (Omega-3) determined an Adequate Intake (AI), to see a benefit, in individuals with hypertension and hypercholesterolemia to be more than 4g/day.

The most current and on-going Alzheimer’s study that is being done by The school of Medicine and The School of Psychology, University of Adelaide, Australia, has incorporated the same exact dosage of Omega-3 used in a study done, in 2007, by The Department of Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden.

The daily intake of Omega-3 in the 2007 and current study is at 2.32g/day of Omega-3 and there is no explanation as to why they believe such dosage was or is optimal.

While Alzheimers and Hypertension are much different in their mechanism of development but their progression is equally enhanced by inflammation and if The US FDA has favored >4g/day in the cases of hypertension, then all others should, at least, evaluate such intake in the studies of Omega-3 and inflammatory or degenerative diseases, Alzheimer’s included.

This recent study, not only has re-opened the chapter on the effectiveness of Omega-3 and the severe cases of Alzheimer’s but also it has re-opened the door to reevaluate many other studies, where the designers of the studies employed inadequate amount and/or short duration.

In conclusion, Nutri-Med Logic Corp agrees with this recent study but adds that not only the duration but the amount of intake is also of paramount importance.

Nutri-Med Logic Corp (http://www.nutrimedlogic.com) is a producer of dietary supplements such as: A Concentrated and Balanced Omega-3, a potent anti-inflammatory nutrient and R-Alpha Lipoic, a potent anti-oxidant nutrient. R-Alpha Lipoic is made and known by the human body;

Nutri-Med Logic’s products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, sources or statements, herein, have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the supplements stated above; nor equate their supplementation to prevention, treatment or cure.

###





More Clinical Psychology Press Releases


Leave a Comment

You must be logged in to post a comment.